FDA Approvals, Patient Selection, and SC Amivantamab
Panelists discuss how recent FDA approvals and SC amivantamab data support broader use of subcutaneous therapy in NSCLC.
The Value of Subcutaneous Therapy for Patients
Panelists discuss how SC delivery enhances patient convenience and health care efficiency in NSCLC treatment.
Sequencing Therapies and Using the Most Effective Options First
Experts discuss the complexities of treatment sequencing in cancer therapy, emphasizing the importance of using the best therapies upfront for optimal outcomes.
Managing Adverse Events and Integrating Amivantamab Plus Lazertinib
Panelists discuss how proactive AE management optimizes safety and adherence with emerging EGFR-targeted regimens.
Subcutaneous Treatments Can Save Chair Time, Decrease Infusion Reaction in NSCLC: Joshua K. Sabari, MD
Subcutaneous therapy could be the future of non–small cell lung cancer (NSCLC) as it would decrease time needed for treatment.
Using AI to Individualize Clinical Pathways Is the Future of Precision Oncology: Joshua K. Sabari, MD
Using artificial intelligence (AI) to specialize treatment for patients with different kinds of cancer can be a boon to clinicians looking to personalize their care.
Clinicians Should Look Beyond NGS When Delivering Precision Oncology: Joshua K. Sabari, MD
New methods of testing tissue and plasma beyond next-generation sequencing (NGS) could be used to deliver the best therapeutic options for patients with cancer.
CNS Penetration and Efficacy of Emerging Therapies
Panelists discuss how CNS-active EGFR TKIs are improving intracranial outcomes and influencing treatment selection in NSCLC.
Impact of Recent Approvals and Novel Mechanisms
Panelists discuss how new dual-targeting agents and TKIs are redefining treatment approaches in EGFR-positive NSCLC.
Overcoming Resistance Mechanisms and Addressing Unmet Needs
Panelists discuss how overcoming resistance to EGFR TKIs requires next-generation inhibitors and more individualized treatment strategies.
Understanding EGFR Mutations and First-Line Treatment
Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine.
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity
Zongertinib shows promising results in HER2-mutant NSCLC, offering high response rates and improved quality of life with minimal toxicity.
